| Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update Q Ying, G Wu Renal failure 39 (1), 474-483, 2017 | 118 | 2017 |
| Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment Q Yu, M Zhang, Q Ying, X Xie, S Yue, B Tong, Q Wei, Z Bai, L Ma Cell death & disease 10 (3), 218, 2019 | 78 | 2019 |
| PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein (a) particles in statin-treated patients with elevated lipoprotein (a) GF Watts, DC Chan, J Pang, L Ma, Q Ying, S Aggarwal, SM Marcovina, ... Metabolism 107, 154221, 2020 | 59 | 2020 |
| New insights into the regulation of lipoprotein metabolism by PCSK9: lessons from stable isotope tracer studies in human subjects Q Ying, DC Chan, GF Watts Frontiers in Physiology 12, 603910, 2021 | 14 | 2021 |
| G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE−/− mice L Qian, L Ma, G Wu, Q Yu, H Lin, Q Ying, D Wen, C Gao Vascular Pharmacology 89, 49-57, 2017 | 14 | 2017 |
| Unravelling lipoprotein metabolism with stable isotopes: tracing the flow Q Ying, DC Chan, PHR Barrett, GF Watts Metabolism 124, 154887, 2021 | 11 | 2021 |
| Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments? Q Ying, A Ronca, DC Chan, J Pang, E Favari, GF Watts European Journal of Clinical Investigation 52 (7), e13766, 2022 | 9 | 2022 |
| PCSK9 inhibition with alirocumab decreases plasma lipoprotein (a) concentration by a dual mechanism of action in statin‐treated patients with very high apolipoprotein (a … Q Ying, DC Chan, J Pang, SM Marcovina, PHR Barrett, GF Watts Journal of Internal Medicine 291 (6), 870-876, 2022 | 6 | 2022 |
| I4, a synthetic anti-diabetes agent, attenuates atherosclerosis through its lipid-lowering, anti-inflammatory and anti-apoptosis properties L Ma, L Qian, Q Ying, Y Zhang, C Zhou, G Wu Molecular and Cellular Endocrinology 440, 80-92, 2017 | 6 | 2017 |
| Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management Q Ying, DC Chan, GF Watts Current Opinion in Lipidology 32 (3), 210-212, 2021 | 4 | 2021 |
| Effect of omega-3 fatty acid supplementation on the postprandial metabolism of apolipoprotein (a) in familial hypercholesterolemia Q Ying, M Croyal, DC Chan, V Blanchard, J Pang, M Krempf, GF Watts Journal of Atherosclerosis and Thrombosis 30 (3), 274-286, 2023 | 3 | 2023 |
| Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies DC Chan, Q Ying, GF Watts Current Opinion in Lipidology 32 (6), 378-385, 2021 | 3 | 2021 |
| Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein (a): Selective effect of eicosapentaenoic acid? NC Ward, Q Ying, DC Chan, J Pang, TA Mori, CJ Schultz, G Dwivedi, ... Journal of Clinical Lipidology 17 (5), 694-699, 2023 | 1 | 2023 |
| Does fish oil supplementation increase cholesterol efflux capacity in familial hypercholesterolaemia? DC Chan, A Ronca, Q Ying, J Pang, M Croyal, GF Watts, E Favari European Journal of Clinical Investigation 53 (10), 2023 | | 2023 |
| Effect of high dose omega-3 fatty acids on arterial inflammation in patients with elevated lipoprotein (A): A pilot study Q Ying, N Ward, D Chan, J Pang, T Mori, C Schultz, G Dwivedi, R Francis, ... Atherosclerosis 379, S20-S21, 2023 | | 2023 |
| Effect of omega-3 fatty acid ethyl esters on postprandial arterial elasticity in patients with familial hypercholesterolemia Q Ying, DC Chan, J Pang, M Croyal, V Blanchard, M Krempf, GF Watts Clinical Nutrition ESPEN 55, 174-177, 2023 | | 2023 |
| Metabolic, Vascular and Therapeutic Aspects of Lipoprotein (a) Q Ying | | 2023 |
| Postprandial apolipoprotein (a) metabolism in familial hypercholesterolaemia: Therapeutic effect of omega-3 fatty acid supplementation Q Ying, M Croyal, DC Chan, V Blanchard, J Pang, M Krempf, GF Watts Atherosclerosis 355, 63-64, 2022 | | 2022 |
